Premium
Serological and immunohistochemical HER‐2/neu statuses do not correlate and lack prognostic value for ovarian cancer patients
Author(s) -
HOOPMANN M.,
SACHSE K.,
VALTER M.M.,
BECKER M.,
NEUMANN R.,
ORTMANN M.,
GÖHRING U.J.,
THOMAS A.,
MALLMANN P.,
SCHÖNDORF T.
Publication year - 2010
Publication title -
european journal of cancer care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.849
H-Index - 67
eISSN - 1365-2354
pISSN - 0961-5423
DOI - 10.1111/j.1365-2354.2009.01112.x
Subject(s) - immunohistochemistry , medicine , her2/neu , ovarian cancer , breast cancer , cancer , pathology , clinical significance , biomarker , oncology , biology , biochemistry
HOOPMANN M., SACHSE K., VALTER M.M., BECKER M., NEUMANN R., ORTMANN M., GÖHRING U.‐J., THOMAS A., MALLMANN P. & SCHÖNDORF T. (2010) European Journal of Cancer Care
Serological and immunohistochemical HER‐2/neu statuses do not correlate and lack prognostic value for ovarian cancer patients The serodiagnostics of extracellular domain (ECD) HER‐2/neu has turned into an evidenced‐based tumour marker for HER‐2/neu‐positive breast cancer patients. This study investigated the clinical relevance of immunohistochemical and serum HER‐2/neu in 44 patients with advanced ovarian cancer. The Hercept‐Test® from DAKO Diagnostics was used to analyse immunohistochemical HER‐2/neu expression. The HER‐2/neu ECD in serum was determined quantitatively by Bayer Immuno 1™ Immunoanalyser. The HER‐2/neu serum values were correlated to the clinical course of disease and to established prognostic factors, i.e. progression‐free and overall survival. Some 23% of patients ( n = 11) expressed HER‐2/neu serum levels higher than 15 ng/mL, whereas only 7.7% ( n = 2) of the patients examined by immunohistochemistry showed a HER‐2/neu overexpression of the tissue. None of them revealed an overexpression of HER‐2/neu ECD by serodiagnostics. HER‐2/neu overexpression did not correlate significantly to any of the analysed prognostic factors. According to progression‐free and overall survival, there was no significant difference between serologically HER‐2/neu‐positive or negative patients. For ovarian cancer patients, neither high HER‐2/neu serum levels, nor immunohistochemically determined HER‐2/neu positivity, appear to predict the course of disease. This study shows a lack of association between the immunohistochemical HER‐2/neu status and the serum level of solute extracelluar HER‐2/neu domain.